Antibacterial activity of extracellular compounds produced by a Pseudomonas strain against methicillin-resistant Staphylococcus aureus (MRSA) strains.

Viviane F Cardozo, Admilton G Oliveira, Erick K Nishio, Marcia R E Perugini, Célia G T J Andrade, Wanderley D Silveira, Nelson Durán, Galdino Andrade, Renata K T Kobayashi, Gerson Nakazato
Author Information
  1. Viviane F Cardozo: Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil.

Abstract

BACKGROUND: The emergence of multidrug-resistant bacteria is a world health problem. Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) strains, is one of the most important human pathogens associated with hospital and community-acquired infections. The aim of this work was to evaluate the antibacterial activity of a Pseudomonas aeruginosa-derived compound against MRSA strains.
METHODS: Thirty clinical MRSA strains were isolated, and three standard MRSA strains were evaluated. The extracellular compounds were purified by vacuum liquid chromatography. Evaluation of antibacterial activity was performed by agar diffusion technique, determination of the minimal inhibitory concentration, curve of growth and viability and scanning electron microscopy. Interaction of an extracellular compound with silver nanoparticle was studied to evaluate antibacterial effect.
RESULTS: The F3 (ethyl acetate) and F3d (dichloromethane- ethyl acetate) fractions demonstrated antibacterial activity against the MRSA strains. Phenazine-1-carboxamide was identified and purified from the F3d fraction and demonstrated slight antibacterial activity against MRSA, and synergic effect when combined with silver nanoparticles produced by Fusarium oxysporum. Organohalogen compound was purified from this fraction showing high antibacterial effect. Using scanning electron microscopy, we show that the F3d fraction caused morphological changes to the cell wall of the MRSA strains.
CONCLUSIONS: These results suggest that P. aeruginosa-produced compounds such as phenazines have inhibitory effects against MRSA and may be a good alternative treatment to control infections caused by MRSA.

References

  1. J Pharm Pharm Sci. 2008;11(4):90-4 [PMID: 19183517]
  2. Ann Clin Microbiol Antimicrob. 2011 Jun 09;10:25 [PMID: 21658242]
  3. Ann Clin Microbiol Antimicrob. 2006 Mar 22;5:5 [PMID: 16553949]
  4. Ann Clin Microbiol Antimicrob. 2012 May 03;11:11 [PMID: 22554280]
  5. J Food Prot. 2009 Feb;72(2):354-9 [PMID: 19350980]
  6. J Antibiot (Tokyo). 2011 May;64(5):395-7 [PMID: 21364597]
  7. J Med Microbiol. 2007 Jul;56(Pt 7):956-963 [PMID: 17577062]
  8. Clin Microbiol Infect. 2003 Dec;9(12):1179-86 [PMID: 14686982]
  9. New Phytol. 2003 Mar;157(3):503-523 [PMID: 33873412]
  10. Ann Clin Microbiol Antimicrob. 2012 Jun 20;11:18 [PMID: 22716026]
  11. J Med Microbiol. 2001 Aug;50(8):732-742 [PMID: 11478678]
  12. Infect Control Hosp Epidemiol. 2007 Nov;28(11):1255-60 [PMID: 17926276]
  13. Int J Infect Dis. 2010 Jul;14(7):e560-6 [PMID: 20047848]
  14. J Nat Prod. 1996 Mar;59(3):293-6 [PMID: 8882433]
  15. Chem Rev. 2004 Mar;104(3):1663-86 [PMID: 15008629]
  16. J Nanobiotechnology. 2005 Jul 13;3:8 [PMID: 16014167]
  17. J Appl Microbiol. 2010 Feb;108(2):703-11 [PMID: 19778345]
  18. J Microbiol. 2011 Dec;49(6):942-9 [PMID: 22203557]
  19. Appl Biochem Biotechnol. 2010 Apr;160(8):2467-74 [PMID: 19578993]
  20. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9865-70 [PMID: 11481426]
  21. Infect Dis Clin North Am. 2011 Mar;25(1):155-79 [PMID: 21315999]
  22. Antimicrob Agents Chemother. 1997 Apr;41(4):850-2 [PMID: 9087504]
  23. ILAR J. 2010;51(3):233-44 [PMID: 21131724]
  24. PLoS One. 2011 Mar 31;6(3):e18031 [PMID: 21483852]
  25. Braz J Infect Dis. 2009 Jun;13(3):165-9 [PMID: 20191190]
  26. J Hosp Infect. 2002 Jun;51(2):126-32 [PMID: 12090800]
  27. J Hosp Infect. 2006 Jun;63(2):124-32 [PMID: 16621137]
  28. Lancet. 2001 Apr 21;357(9264):1225-40 [PMID: 11418146]
  29. Annu Rev Phytopathol. 2006;44:417-45 [PMID: 16719720]
  30. Vector Borne Zoonotic Dis. 2011 Apr;11(4):327-39 [PMID: 20925523]
  31. Expert Opin Investig Drugs. 2008 Mar;17(3):297-302 [PMID: 18321229]
  32. Braz J Infect Dis. 2001 Aug;5(4):163-70 [PMID: 11712960]
  33. Oman Med J. 2011 Sep;26(5):319-23 [PMID: 22125725]
  34. J Antibiot (Tokyo). 2009 Nov;62(11):621-4 [PMID: 19798118]
  35. Braz J Infect Dis. 2004 Feb;8(1):25-79 [PMID: 15286878]
  36. J Antibiot (Tokyo). 2008 Sep;61(9):577-82 [PMID: 19160527]
  37. Open Microbiol J. 2011;5:96-106 [PMID: 21915230]

MeSH Term

Acetates
Anti-Bacterial Agents
Cell Wall
Drug Evaluation, Preclinical
Drug Synergism
Fusarium
Halogens
Metal Nanoparticles
Methicillin-Resistant Staphylococcus aureus
Methylene Chloride
Microbial Viability
Phenazines
Pseudomonas aeruginosa
Silver

Chemicals

Acetates
Anti-Bacterial Agents
Halogens
Phenazines
phenazine-1-carboxamide
Silver
Methylene Chloride
ethyl acetate